Myorelaxant effects of eperisone and diazepam in the treatment of acute spinal muscle contracture: A comparative study

Journal of Anaesthesiology Clinical Pharmacology

Volumn 24, Issue 3, 2008, Pages 285-290

  Viladot Perice R ^a,b,c   Rodriguez Boronat, E ^a,b,c   Ferrer Bosch, F ^a,b,c   Colomer Rusinyol, F ^a,b,c  

^a Traumatology and Orthopaedic Service

^b Traumatology Service

^c Hospital Municipal de Badalona   (Spain)

Author keywords

Diazepam; Eperisone; Myorelaxant; Spinal muscle contracture

Indexed keywords

DIAZEPAM; EPERISONE;

ADULT; ARTICLE; BACK MUSCLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EPIGASTRIC PAIN; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MUSCLE CONTRACTURE; MUSCLE RELAXATION; PALPATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOMNOLENCE; TACHYCARDIA; URINE RETENTION; VERTIGO; WORK CAPACITY;

EID: 48349113638     PISSN: 09709185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Abbruzzese G. The medical management of spasticity. Eur J Neurol 2002; 9 (Suppl 1): 30-4..
2. Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle Nerve Suppl 1997; 6: S92-120.
3. Taricco M, Pagliacci MC, Telaro E, Adone R. Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review. Eura Medicophys 2006; 42: 5-15.
4. Morikawa K, Oshita M, Yamazaki M, Ohara N, Mizutani F, Kato H, Ito Y, Kontani H, Koshiura R. Pharmacological studies of the new centrally acting muscle relaxant 4′-ethyl-2-methyl-3-pyrrolidino-propiophenone hydrochloride. Arzneimittelforschung 1987; 37: 331-6.
5. Matsunaga M, Uemura Y, Yonemoto Y, Kanai K, Etoh H, Tanaka S, Atsuta Y, Nishizawa Y, Yamanishi Y. Long-lasting muscle relaxant activity of eperisone hydrochloride after percutaneous administration in rats. Jpn J Pharmacol 1997; 73: 215-20.
6. Iwase S, Mano T, Saito M, Ishida G. Effect of a centrally-acting muscle relaxant, eperisone hydrochloride, on muscle sympathetic nerve activity in humans. Funct Neurol 1992; 7: 459-70.
7. Farkas S. Silperisone: a centrally acting muscle relaxant. CNS Drug Rev 2006; 12: 218-35.
8. Kocsis P, Farkas S, Fodor L, Bielik N, Thán M, Kolok S, Gere A, Csejtei M, Tarnawa I. Tolperisonetype drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther 2005; 315: 1237-46.
9. Nakagawa M, Nakahara K, Maruyama Y, Kawabata M, Higuchi I, Kubota H, Izumo S, Arimura K, Osame M. Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/ tropical spastic paraparesis. J Neurovirol 1996; 2: 345-55.
10. Murayama K, Katsumi T, Tajika E, Nakamura T. Clinical application of eperisone hydrochloride to neurogenic bladder. Hinyokika Kiyo 1984; 30: 403-8.
11. Kobayashi Y, Kawasaki T, Yoshimi T, Nakajima T, Kanai K. Muscle cramps in chronic liver diseases and treatment with antispastic agent (eperisone hydrochloride). Dig Dis Sci 1992; 37: 1145-6.
12. 3onkowski A, Mirowska D. Pharmacotherapy for spasticity. Ortop Traumatol Rehabil 2002; 4: 54-6.
13. Kita M, Goodkin DE. Drugs used to treat spasticity. Drugs 2000; 59: 487-95.
14. Dones I, Nazzi V, Broggi G. The guidelines for the diagnosis and treatment of spasticity. J Neurosurg Sci 2006; 50: 101-5.
15. Waldman HJ. Centrally acting skeletal muscle relaxants and associated drugs. J Pain Symptom Manage 1994; 9: 434-41.